Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in Indonesia
Introduction. Tenofovir disoproxil fumarate (tenofovir) and telbivudine are two available nucleos(t)ide analogue (NA) for the treatment of chronic hepatitis B (CHB) patients. Tenofovir has been known as a nephrotoxic agent in HIV patients, but still controversy in CHB patients. On the other hand, te...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Indonesian |
| Published: |
Department of Internal Medicine, Faculty of Medicine Universitas Indonesia
2018-09-01
|
| Series: | Jurnal Penyakit Dalam Indonesia |
| Subjects: | |
| Online Access: | http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/213/160 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850160878295449600 |
|---|---|
| author | Rino Alvani Gani |
| author_facet | Rino Alvani Gani |
| author_sort | Rino Alvani Gani |
| collection | DOAJ |
| description | Introduction. Tenofovir disoproxil fumarate (tenofovir) and telbivudine are two available nucleos(t)ide analogue (NA) for the treatment of chronic hepatitis B (CHB) patients. Tenofovir has been known as a nephrotoxic agent in HIV patients, but still controversy in CHB patients. On the other hand, telbivudine had a renal protective effect and increased estimated glomerular filtration rate (eGFR). This studi aimed to address the renal safety of tenofovir and telbivudine in Indonesian patients.
Method. A retrospective cohort study design was conducted in CHB patients who prescribed with tenofovir or telbivudine from January 2013 to December 2016. Patients who met the inclusion and exclusion criteria were followed up for one year. The serial evaluation of creatinine serum was collected in week-24 and week-48 after the administration of tenofovir or telbivudine.
Results. Among CHB patients, 68 and 62 patients that prescribed with tenofovir or telbivudine, respectively, were enrolled in this study. Serum creatinine level was increased in tenofovir group from 0.88 (SD 0.17) mg/dL at baseline to 0.93 (SD 0.22) mg/dL after 24 weeks (p = 0.02), but creatinine trend to reach plateau after 48 weeks. However, in telbivudine group, serum creatinine level was decreased from 0.85 (SD 0.21) mg/dL at baseline to 0.80 (SD 0.18) mg/dL after 48 weeks (p = 0.003).
Conclusion. Tenofovir is associated with the increased of creatinine serum and decreased of eGFR in CHB patients with eGFR ≥60 mL/menit/1,73 m2. |
| format | Article |
| id | doaj-art-f83e43cd0f144108957a5a246d2eb208 |
| institution | OA Journals |
| issn | 2406-8969 2549-0621 |
| language | Indonesian |
| publishDate | 2018-09-01 |
| publisher | Department of Internal Medicine, Faculty of Medicine Universitas Indonesia |
| record_format | Article |
| series | Jurnal Penyakit Dalam Indonesia |
| spelling | doaj-art-f83e43cd0f144108957a5a246d2eb2082025-08-20T02:23:01ZindDepartment of Internal Medicine, Faculty of Medicine Universitas IndonesiaJurnal Penyakit Dalam Indonesia2406-89692549-06212018-09-0153129134http://dx.doi.org/10.7454/jpdi.v5i3.213Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in IndonesiaRino Alvani Gani0Divisi Hepatobilier, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia, Rumah Sakit Pusat Nasional Cipto Mangunkusumo, Jakarta IndonesiaIntroduction. Tenofovir disoproxil fumarate (tenofovir) and telbivudine are two available nucleos(t)ide analogue (NA) for the treatment of chronic hepatitis B (CHB) patients. Tenofovir has been known as a nephrotoxic agent in HIV patients, but still controversy in CHB patients. On the other hand, telbivudine had a renal protective effect and increased estimated glomerular filtration rate (eGFR). This studi aimed to address the renal safety of tenofovir and telbivudine in Indonesian patients. Method. A retrospective cohort study design was conducted in CHB patients who prescribed with tenofovir or telbivudine from January 2013 to December 2016. Patients who met the inclusion and exclusion criteria were followed up for one year. The serial evaluation of creatinine serum was collected in week-24 and week-48 after the administration of tenofovir or telbivudine. Results. Among CHB patients, 68 and 62 patients that prescribed with tenofovir or telbivudine, respectively, were enrolled in this study. Serum creatinine level was increased in tenofovir group from 0.88 (SD 0.17) mg/dL at baseline to 0.93 (SD 0.22) mg/dL after 24 weeks (p = 0.02), but creatinine trend to reach plateau after 48 weeks. However, in telbivudine group, serum creatinine level was decreased from 0.85 (SD 0.21) mg/dL at baseline to 0.80 (SD 0.18) mg/dL after 48 weeks (p = 0.003). Conclusion. Tenofovir is associated with the increased of creatinine serum and decreased of eGFR in CHB patients with eGFR ≥60 mL/menit/1,73 m2.http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/213/160Hepatitis BRenal functionTelbivudineTenofovir |
| spellingShingle | Rino Alvani Gani Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in Indonesia Jurnal Penyakit Dalam Indonesia Hepatitis B Renal function Telbivudine Tenofovir |
| title | Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in Indonesia |
| title_full | Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in Indonesia |
| title_fullStr | Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in Indonesia |
| title_full_unstemmed | Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in Indonesia |
| title_short | Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in Indonesia |
| title_sort | comparison of renal safety of tenofovir and telbivudine in chronic hepatitis b patients a real world study in indonesia |
| topic | Hepatitis B Renal function Telbivudine Tenofovir |
| url | http://jurnalpenyakitdalam.ui.ac.id/index.php/jpdi/article/view/213/160 |
| work_keys_str_mv | AT rinoalvanigani comparisonofrenalsafetyoftenofovirandtelbivudineinchronichepatitisbpatientsarealworldstudyinindonesia |